At least one in four contemporary songs references alcohol, according to an analysis of multiple studies that hints at the effects of music exposure on listeners’ drinking.
The award recognizes Saphire's leadership and innovative research toward addressing the urgent need for effective antibody therapeutics against COVID-19 and viral threats such as Ebola and Lassa virus.
The Inamori International Center for Ethics and Excellence at Case Western Reserve University will award Dr. Anthony Fauci, a physician, immunologist, and infectious disease expert, with the 2024 Inamori Ethics Prize.
Researchers propose a new way of understanding how diseases spread between animals and humans, by focusing on the effect that agriculture, ecological and sociopolitical factors have on disease emergence and transmission.
The study, led by scientists at La Jolla Institute for Immunology (LJI), reveals the inner workings of viral factories, clusters of viral proteins and genomes that form in host cells.
Later this summer, staff members at Cedars-Sinai Marina del Rey Hospital will spring into action when a pretend patient comes to the Emergency Department with symptoms of a virus like Ebola, one of the deadliest, most infectious diseases on the planet.
Title 42, the United States pandemic rule that had been used to immediately deport hundreds of thousands of migrants who crossed the border illegally over the last three years, has expired. Those migrants will have the opportunity to apply for asylum. President Biden's new rules to replace Title 42 are facing legal challenges. Border crossings have already risen sharply, as many migrants attempt to cross before the measure expires on Thursday night. Some have said they worry about tighter controls and uncertainty ahead. Immigration is once again a major focus of the media as we examine the humanitarian, political, and public health issues migrants must go through.
Researcher will discuss the study which involved a sleeping aid known as suvorexant that is already approved by the Food and Drug Administration (FDA) for insomnia, hints at the potential of sleep medications to slow or stop the progression of Alzheimer’s disease.
Discover BMB, the annual meeting of the American Society for Biochemistry and Molecular Biology, will feature award lectures by high-profile speakers discussing noteworthy research, education and diversity initiatives. The meeting will take place March 25–28 in Seattle.
Inmazeb (REGN-EB3), developed by Regeneron, is a three-antibody cocktail designed to target the Ebola virus glycoprotein. The drug was first approved for clinical use in October 2020, but its exact mechanism of action has remained unclear.
The Wildlife Conservation Society (WCS) released an image of scientists taking a swab from a straw-colored fruit bat (Eidolon helvum) to test it for zoonotic diseases such as the Ebola virus.
MedStar Washington Hospital Center has opened a new state-of-the-art Biocontainment Unit (BCU) to care for patients who contract highly infectious diseases. Located near the Emergency Room, the new multi-purpose 15-bed unit will be used primarily for observation and flexed for respiratory isolation and further flexed to care for patients with highly contagious conditions, such as Ebola.
A Sudan ebolavirus vaccine and antibody therapeutic tested at Texas Biomedical Research Institute have been sent to Uganda as part of efforts to control the outbreak there.
Once considered a potentially static field of medicine, the discipline of studying infectious diseases has proven to be dynamic as emerging and reemerging infectious diseases present continuous challenges, Anthony S. Fauci, M.D., writes in a perspective in The New England Journal of Medicine.
Research scientist Bobby Brooke Herrera, renowned for developing tools to accelerate diagnosis and treatment of infectious diseases such as COVID-19, has joined Rutgers Global Health Institute.
Ricardo Rajsbaum understands killers. Like a criminal investigator tracking prey, the Rutgers virologist spends his days researching the enemy. Rather than obsessing over a madman’s next move, however, Rajsbaum’s focus is on the microscopic viruses that infect human cells – sometimes with deadly consequences.
Several years ago, a team of scientists at Lehigh University developed a predictive model to accurately forecast Ebola outbreaks based on climate-driven bat migration.
Researchers at the University of Illinois Chicago are working with the National Institutes of Health and University of Minnesota to establish a center for antiviral drug development for pandemic-level viruses, including Ebola and SARS-CoV-2.
In a new study, researchers show how a critical Lassa virus protein, called polymerase, drives infection by harnessing a cellular protein in human hosts. Their work suggests future therapies could target this interaction to treat patients.
Helical nucleocapsids in infected cells are composed of Marburg viral genomic RNA and nucleoproteins, or NPs, that are structurally similar to those of the Ebola virus. Future drug development may be possible based on the targeting of nucleocapsid formation, which may inhibit the Marburg virus' ability to replicate.
A new tool can quickly and reliably identify the presence of Ebola virus in blood samples, according to a study by researchers at Washington University School of Medicine in St. Louis and colleagues at other institutions.
Ebola virus polymerase hijacks a cellular protein called GSPT1. An experimental drug that targets GSPT1 for degradation can also halt Ebola virus infection in human cells.
The team's latest study, published in Cell, shows that two clever human antibodies can target two ebolavirus species at once: Ebola virus and Sudan virus. These two species are responsible for the biggest, deadliest outbreaks. The new report suggests researchers could combine these two potent antibodies to make a powerful antiviral therapy.
A new study by UCLA researchers and colleagues demonstrates that the Ebola vaccine known as rVSVΔG-ZEBOV-GP results in a robust and enduring antibody response among vaccinated individuals in areas of the Democratic Republic of Congo (DRC) that are experiencing outbreaks of the disease. Among the more than 600 study participants, 95.6% demonstrated antibody persistence six months after they received the vaccine.
The study is the first published research examining post–Ebola-vaccination antibody response in the DRC, a nation of nearly 90 million. While long-term analyses of the study cohort continue, the findings will help inform health officials’ approach to vaccine use for outbreak control, the researchers said.
• Researchers have identified a set of receptors shared across human, mosquito, and other animal cells for the eastern equine encephalitis virus (EEEV) and two related viruses, a crucial first step for developing preventive and curative treatments.
• In experiments with cells and mouse models with a related virus, the scientists were able to prevent infection and disease progression using decoy molecules to hamper viral entry into cells.
• In a 2019 outbreak of eastern equine encephalitis (EEE, or triple E) in New England, 30 percent of infected people died and half of those who survived had long-term neurologic damage.
• Done between major outbreaks, this type of research into highly pathogenic viruses with pandemic potential can help improve preparedness for future outbreaks.
A nationwide team of researchers, led by scientists at University of Utah Health and The Rockefeller University, has determined how a genetic mutation found in mice and monkeys interferes with viruses such as HIV and Ebola. They say the finding could eventually lead to the development of medical interventions in humans.
A family of proteins best known for their role in diminishing HIV infectivity may have the goods to outwit other emerging and re-emerging viruses, scientists have found.
Expert Q&A: Do breakthrough cases mean we will soon need COVID boosters? The extremely contagious Delta variant continues to spread, prompting mask mandates, proof of vaccination, and other measures. Media invited to ask the experts about these and related topics.
The Global Virus Network (GVN), representing 63 Centers of Excellence and 11 Affiliates in 34 countries comprising foremost experts in every class of virus causing disease in humans, and the Institut de Recherche en Santé, de Surveillance Epidémiologique et de Formation [Institute for Health Research, Epidemiological Surveillance and Training], or the IRESSEF, announced the addition of the IRESSEF as GVN’s newest Center of Excellence.
Mount Sinai researchers have uncovered the complex cellular mechanisms of Ebola virus, which could help explain its severe toll on humans and identify potential pathways to treatment and prevention. In a study published in mBio, the team reported how a protein of the Ebola virus, VP24, interacts with the double-layered membrane of the cell nucleus (known as the nuclear envelope), leading to significant damage to cells along with virus replication and the propagation of disease.
Scientists have a general idea of how viruses invade and spread in the body, but the precise mechanisms are actually not well understood, especially when it comes to Ebola virus. Olena Shtanko, Ph.D., a Staff Scientist at the Texas Biomedical Research Institute (Texas Biomed), has received more than $1 million from the National Institutes of Health (NIH) to explore different aspects of Ebola virus infection.
Researchers are developing a new sensor that can detect Ebola in a single drop of blood and provides results in just an hour. With further development, the technology might also enable fast and inexpensive detection of other viruses, including the virus that causes COVID-19.
&T's National Biodefense Analysis and Countermeasures Center designed and conducted a study to optimize methods for collecting and measuring very small amounts of Ebola virus in the air.
In a new Cell Reports study, researchers at La Jolla Institute for Immunology demonstrate how Ebola virus has found a different way to get things done. The virus encodes only eight proteins but requires dozens of functions in its lifecycle. The new study shows how one of Ebola virus’s key proteins, VP40, uses molecular triggers in the human cell to transform itself into different tools for different jobs.
A novel computer algorithm that could create a broadly reactive influenza vaccine for swine flu also offers a path toward a pan-influenza vaccine and possibly a pan-coronavirus vaccine as well, according to a new paper published in Nature Communications.
Researchers have identified a previously unknown site on the filovirus glycoprotein to which small drug molecules can bind and prevent infection -- blocking both sites may be more a more effective treatment with reduced risk of side effects.
As the world grapples with COVID-19, the Ebola virus is again raging. A research team at University of Delaware is using supercomputers to simulate the inner workings of Ebola (as well as COVID-19), looking at how molecules move, atom by atom, to carry out their functions. Now, they have revealed structural features of the Ebola virus’s protein shell to provide therapeutic targets to destabilize the virus and knock it out with an antiviral treatment.
Scientists at the University of Delaware report a computational study of a nucleocapsid found in the Ebola virus and show that the binding of the ssRNA allows the nucleocapsid to maintain its shape and structural integrity.
Even after heroic medical and societal efforts finally break the back of the current COVID-19 pandemic, the global sigh of relief may not last long. The chilling reality is that viral threats are growing more common. And they’re getting deadlier.
Global health scholars have issued a clarion call about the needless loss of life expected because of a foreseeable prospect of “slow and inadequate access to supplies” to control COVID-19 in sub-Saharan Africa. They say what is unfolding now is similar to when lifesaving diagnostics and treatments came to the region long after they were available elsewhere.
Each year since 2008, SCT has awarded the David Sackett Trial of the Year Award to a randomized, controlled trial published (either electronically or in print) in the previous calendar year. The 2020 recipient is Pamoja Tulinde Maisha (PALM [“Together Save Lives”] in the Kiswahili language) trial.
UCLA Health is one of 75 sites around the globe participating in a clinical trial sponsored by the National Institutes of Health to test the effectiveness of a candidate anti-viral drug against COVID-19.
After the Ebola virus tore through western Africa in 2015, two UC Santa Barbara researchers studied the xenophobia of the disease generated among people who had almost zero chance of being infected by it.
A group of University of Alberta researchers who have discovered why the drug remdesivir is effective in treating the coronaviruses that cause Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS) expect it might also be effective for treating patients infected with the new COVID-19 strain.